Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Descriptive human anatomy often uses terminology that is fairly correct descriptive Latin. For example, musculus gluteus maximus simply means the "largest rump muscle", where musculus was Latin for "little mouse" and applied to muscles; a frenum, a structure for keeping something in place, is Latin for bridle; and a foramen is Latin for a passage or perforation.
American chemist and psychopharmacologist Alexander Shulgin reported he synthesized MDMA in 1965 while researching methylenedioxy compounds at Dow Chemical Company, but did not test the psychoactivity of the compound at this time. Around 1970, Shulgin sent instructions for N-methylated MDA (MDMA) synthesis to the founder of a Los Angeles chemical company who had requested them. This individual later provided these instructions to a client in the Midwest. Shulgin may have suspected he played a role in the emergence of MDMA in Chicago. Shulgin first heard of the psychoactive effects of N-methylated MDA around 1975 from a young student who reported "amphetamine-like content". Around 30 May 1976, Shulgin again heard about the effects of N-methylated MDA, this time from a graduate student in a medicinal chemistry group he advised at San Francisco State University who directed him to the University of Michigan study. She and two close friends had consumed 100 mg of MDMA and reported positive emotional experiences. Following the self-trials of a colleague at the University of San Francisco, Shulgin synthesized MDMA and tried it himself in September and October 1976. Shulgin and David E. Nichols first reported on MDMA and its psychoactive effects in humans in a presentation at a conference in Bethesda, Maryland in December 1976. This conference paper was subsequently formally published in 1978.
This aspect of the book has become known to a wider public through Kermani's repeated tributes to Father Paolo and his order, for example in Kermani's highly acclaimed German Publishers Association Peace Prize speech.
Sources: en.wikipedia.org
== Adverse effects == The adverse-event profile of ceftolozane/tazobactam from two phase II trials (comparing either ceftolozane alone or in combination with tazobactam to ceftazidime or meropenem) suggests that ceftolozane/tazobactam is well tolerated. The most common adverse effects reported with ceftolozane/tazobactam are headache (5.8%), constipation (3.9%), hypertension (3%), nausea (2.8%), and diarrhea (1.9%).
=== Effects on antigenicity of milk proteins === A study in 2012 posed the question of whether or not Lactobacillus delbrueckii subsp. bulgaricus had any effect on the antigenicity of four kinds of milk proteins, being α-lactalbumin (α-LA), β-lactoglobulin (β-LG), α-casein (α-CN), and β-casein (β-CN). These proteins are the main proteins found in cow's milk and are known to have antigenic properties in humans, especially young children and infants. 2–5% of young children and infants experience cow's milk protein allergy (CMPA), which has harmful effects on their development and may even result in death. This allergy is facilitated through the antigenicity of the milk proteins, which is the ability of the proteins to trigger an immune response in the body that can result in a number of possible allergic reactions. The study was performed by simulating digestion of unfermented milk and milk that was fermented through exposure to Lactobacillus delbrueckii subsp. bulgaricus to compare their antigenicities in order to see if fermentation had any effect on the antigenicity of the proteins. The antigenicities were measured through an enzyme-linked immunosorbent assay (ELISA). The results claimed that the fermentation of cow's milk by Lactobacillus delbrueckii subsp. bulgaricus reduced the antigenicity of α-LA and β-CN. However, it also increased the antigenicity of α-CN while β-LG was not impacted.
== In human culture == The third island on Kunming Lake at Beijing's Summer Palace is called Zaojian Tang Dao (藻鑒堂島). The name comes from the classical Chinese character 藻, meaning both "algae" and "literary talent." As a result the islands name can be translated to either "Island of the Algae-Viewing Hall" or "Island of the Hall for Reflecting on Literary Talent."
== β-Lipotropin == β-Lipotropin is a 90-amino acid polypeptide that is the carboxy-terminal fragment of POMC. It was initially reported to stimulate melanocytes to produce melanin. It was also reported to perform lipid-mobilizing functions such as lipolysis and steroidogenesis. However, no subsequent studies have been published that support these early findings and no receptor has been identified for β-lipotropin. β-Lipotropin can be cleaved into smaller peptides. In humans, γ-lipotropin, β-MSH, and β-endorphin, are all possible fragments of β-lipotropin. β-endorphin is the predominant opioid of the anterior human and rat pituitary gland. Birdsall and Hulme demonstrated that the C-fragment of lipotropin (β-endorphin) has a high affinity for opiate receptors in the brain, and the binding was reversed by naloxone, a classical antagonist of the opiates (Bradbury et al. 1976a). Alongside this, Feldberg found that β-endorphin administered in cat ventricles was 100 times more potent than morphine as an analgesic agent (Feldberg & Smyth 1976, 1977) and the analgesia persisted for several hours. Feldberg concluded that β-endorphin was the most potent analgesic agent known. β-Lipotropin is found in essentially equimolar concentrations to that of corticotropin. Evidence shows that β-Lipotropin is metabolized into endorphins that can greatly affect mood and behavior and is thus regarded as a prohormone.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.